Page 6 - Serum Institute Of India

New price good, but Rs 250 a dose better: Covid-19 vaccine makers

Centre has ordered 660 mn doses, expected to be supplied between Aug & Dec

No application received for EU authorisation of Covishield: Drug regulator

The European Medicines Agency (EMA) hasn't got any application to authorise Covishield, the vaccine made by the Serum Institute of India

Small contract manufacturers wait to take a shot at Covid vaccines

A host of lesser-known vaccine makers are eyeing contract manufacturing opportunities for global and domestic majors

Serum Institute partners with RDIF to make 300 mn doses of Sputnik V

RDIF says SII can make combination doses of Astra-Sputnik in future

Serum Institute to start manufacturing Sputnik vaccine in September

Serum Institute of India (SII) will start production of Sputnik vaccine at the company's facilities in September, Russian Direct Investment Fund (RDIF) said on Tuesday

Covishield vaccine out of stock at Pune vaccination centres amid shortage

Amid a shortage of Covid-19 vaccines in state, the Pune mayor on Sunday said that the Covishield will not be available at any vaccination centre under jurisdiction of Pune Municipal Corporation today

Top headlines: Indian SPACs to raise $1 bn, SII to double vax production

Business Standard brings you the top headlines on Monday

Serum Institute may double production of AstraZeneca-Oxford vaccine in 2022

Expect 200-million AstraZeneca vaccine doses next year

Covovax denied trials on children; no nod needed for Sputnik Light

The decision comes as a setback to SII, which had sought permission to start a pediatric clinical trial of Covovax

Govt panel recommends against SII testing Covovax on 2-17 age group: Report

"The Subject Expert Committee on Covid-19 of Central Drugs Standard Control Organisation, which deliberated on the application, noted that vaccine has not been approved in any country", a source said

Serum Institute applies for EU nod through drugmaker AstraZeneca

SII Chief Executive Officer Adar Poonawalla said on Mon­day he had taken it up at the "highest levels".

Blurred picture

The sharp cuts in vaccine supply projections are baffling

Taken up Covishield travel issue at highest levels: Adar Poonawalla

Reports suggest India plans to take this matter of non-inclusion of Covishield in the list of approved vaccines for European Union (EU) 'Green Pass' up with the EU

SII manufacturing first batch of Covovax Covid-19 vaccine, says Poonawalla

In March this year, he had said that the clinical trials of Covovax vaccine have begun in India and the company hopes to launch it by September this year.

A jab at veracity

States should not aim to artificially push vaccination numbers

WHO working with AstraZeneca, SII, Indian govt to restart vax shipment

The WHO is urgently trying to work with AstraZeneca, Serum Institute of India (SII) as well as the Indian government to restart shipments of Covid-19 vaccines to countries

AstraZeneca Covid-19 vaccine faces more supply hurdles, now from Thailand

Thailand was slated to receive and administer 6 million AstraZeneca vaccine doses in June but health authorities this week said they would be distributing only 3.5 million of those shots this month

Serum to start clinical trials of Novavax shot for children in July: Report

This week Novavax Inc announced that its vaccine has turned out to be more than 90 per cent effective in clinical trials conducted in the US.

How Biological E could emerge as game changer in India's vaccine race

Company scales up its ambition after government advanced it Rs 1,500 crore for 300 million doses of its vaccine candidate.

Covid-19 vaccine pricing accounts for last-mile delivery, say firms

The cost of logistics is built into the final price of the vaccine, especially when supplying to the private sector